Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
12/9/24 | Enanta Pharmaceuticals (ENTA) | EDP-938 for Respiratory Syncytial Virus (RSV) Treatment | Subscribers Only | Subscribers Only | Subscribers Only |
12/8/24 | Novartis (NVS) | Scemblix for Chronic Myelogenous Leukemia (CML) | Subscribers Only | Subscribers Only | Subscribers Only |
12/8/24 | Johnson & Johnson (JNJ) | Tecvayli for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
12/7/24 | Novo Nordisk (NVO) | Etavopivat for Sickle Cell Anemia | Subscribers Only | Subscribers Only | Subscribers Only |
12/4/24 | Eli Lilly (LLY) | Zepbound for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
02/29/2024 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
09/12/2024 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
09/30/2024 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
10/16/2024 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
10/26/2024 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |